Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey

doi:10.3748/wjg.v27.i12.1226

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7387)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

439

WORD

245

HTML

3531

Figures (1-2)

474

Tables (1-4)

397

Sum=5086

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

622

Download

1679

Sum=2301

Mar 28, 2021 (publication date) through Feb 17, 2025

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Mar 28, 2021; 27(12): 1226-1239
Published online Mar 28, 2021. doi: 10.3748/wjg.v27.i12.1226

Table 2 Demographic, clinical and treatment characteristics from the whole sample of patients

Characteristics	n = 3568 (%)
Age (yr)	38.1 ± 12.3
0-9	10 (0.3)
10-19	120 (3.4)
20-29	769 (21.6)
30-39	1214 (34)
40-49	848 (23.8)
50-59	379 (10.6)
60-69	177 (5.0)
≥ 70	51 (1.4)
Sex
Male	1238 (34.7)
Smoking	183 (5.1)
Clinical risk factors
Hypertension	402 (11.3)
Diabetes	119 (3.3)
Cardiovascular disease	107 (3.0)
Chronic pulmonary disease	164 (4.6)
Recent abdominal surgery for IBD (< 30 d)	136 (3.8)
Overall IBD medications
No medication	339 (9.5)
Oral steroids	473 (13.3)
5-ASA	1221 (34.2)
AZA/6-MP/MTX	1169 (32.8)
Biologics	1832 (51.3)
Therapeutic regimen
Oral steroids monotherapy¹	83 (2.3)
5-ASA monotherapy¹	758 (21.2)
5-ASA + oral steroids²	115 (15.2)
AZA/6-MP/MTX monotherapy¹	556 (15.6)
AZA/6-MP/MTX + oral steroids²	90 (16.2)
Biologic monotherapy¹	1219 (34.2)
Biologic + oral steroids²	100 (8.2)
Combo therapy³	613 (17.2)
Combo therapy³ + oral steroids¹	85 (13.9)
COVID-related complications risk
Highest	768 (23.4)
Moderate	1965 (55.1)
Lowest	836 (21.5)

¹Monotherapy indicates no concomitant biologics or immunomodulator.

²These subcategories represent the frequency of patients in each monotherapy regimen requiring oral steroids.

³Combo therapy refers to biologics plus aminosalicylates/6-mercaptopurine/methotrexate.

5-ASA: Aminosalicylates; AZA: Azathioprine; 6-MP: 6-Mercaptopurine; MTX: Methotrexate; COVID: Coronavirus disease; IBD: Inflammatory bowel disease.

Citation: Queiroz NSF, Teixeira FV, Motta MP, Chebli LA, Hino AAF, Martins CA, Quaresma AB, Silva AAPD, Damião AOMC, Saad-Hossne R, Kotze PG. Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey. World J Gastroenterol 2021; 27(12): 1226-1239
URL: https://www.wjgnet.com/1007-9327/full/v27/i12/1226.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i12.1226